

frequent and routine amendments are necessary to keep them operationally current. Therefore, this regulation—(1) is not a “significant regulatory action” under Executive Order 12866; (2) is not a “significant rule” under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a Regulatory Evaluation as the anticipated impact is so minimal. Since this is a routine matter that will only affect air traffic procedures and air navigation, it is certified that this rule will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

#### List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).

#### Adoption of the Amendment

■ In consideration of the foregoing, the Federal Aviation Administration amends 14 CFR part 71 as follows:

#### **PART 71—DESIGNATION OF CLASS A, CLASS B, CLASS C, CLASS D, AND CLASS E AIRSPACE AREAS; ROUTES; AND REPORTING POINTS.**

■ 1. The authority citation for 14 CFR part 71 continues to read as follows:

**Authority:** 49 U.S.C. 106(g), 40103, 40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, 1959–1963 Comp., p. 389; 14 CFR 11.69.

#### **§ 71.1 [Amended]**

■ 2. The incorporation by reference in 14 CFR 71.1 of the Federal Aviation Administration Order 7400.9 N, Airspace Designations and Reporting Points, dated September 1, 2005, and effective September 15, 2005, is amended as follows:

*Paragraph 6005 Class E airspace areas extending upward from 700 feet or more above the surface of the earth*

\* \* \* \* \*

#### **AWP CA E5 Palm Springs, CA [Modify]**

Palm Springs, CA

(Lat. 33°49'46" N., long. 116°30'24" W.)

That airspace extending upward from 700 feet above the surface beginning at the lat. 34°05'00" N., long. 116°34'03" W.; to lat. 34°08'00" N., long. 116°30'00" W.; to lat. 34°06'42" N., long. 116°28'49" W.; to lat. 34°03'00" N., long. 116°31'00" W.; to lat. 33°42'45" N., long. 115°53'34" W.; to lat. 33°26'00" N., long. 116°09'33" W.; to lat. 33°55'00" N., long. 116°46'03" W., to the point of beginning.

\* \* \* \* \*

Issued in Los Angeles, California, on March 3, 2006.

**Stephen J. Lloyd,**

*Acting Area Director, Western Terminal Operations.*

[FR Doc. 06–2880 Filed 3–23–06; 8:45 am]

**BILLING CODE 4910–13–M**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **Food and Drug Administration**

#### **21 CFR Part 1271**

[Docket No. 1997N–0484S]

**RIN 0910–AB27**

#### **Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products; Correction**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Correcting amendment.

**SUMMARY:** The Food and Drug Administration (FDA) is correcting a final rule that published in the *Federal Register* of May 25, 2004 (69 FR 29786). The final rule required human cell, tissue, and cellular and tissue-based product (HCT/P) establishments to screen and test cell and tissue donors for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases. The document was published with an error in the codified section. This document corrects that error.

**DATES:** Effective on March 24, 2006.

**FOR FURTHER INFORMATION CONTACT:** Paula S. McKeever, Center for Biologics Evaluation and Research (HFM–17), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852–1448, 301–827–6210.

**SUPPLEMENTARY INFORMATION:** The final regulations that are the subject of this correction require HCT/P establishments to screen and test cell and tissue donors for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases. The final regulations incorrectly list a cross-reference in 21 CFR 1271.75(d)(1). This error may prove to be misleading because it inaccurately limits a referenced provision. Therefore, the error needs to be corrected.

#### **List of Subjects in 21 CFR Part 1271**

Biologics, Drugs, Human cells and tissue-based products, Medical devices, Reporting and recordkeeping requirements.

■ Accordingly, 21 CFR part 1271 is corrected by making the following correcting amendment:

#### **PART 1271—HUMAN CELLS, TISSUES, AND CELLULAR AND TISSUE-BASED PRODUCTS**

■ 1. The authority citation for part 1271 continues to read as follows:

**Authority:** 42 U.S.C. 216, 243, 263a, 264, 271.

■ 2. Amend paragraph (d)(1) of § 1271.75 by removing “(a)(1)(i)” and adding in its place “(a)(1)”.

Dated: March 17, 2006.

**Jeffrey Shuren,**

*Assistant Commissioner for Policy.*

[FR Doc. 06–2841 Filed 3–23–06; 8:45 am]

**BILLING CODE 4160–01–S**

## **DEPARTMENT OF THE TREASURY**

### **Internal Revenue Service**

#### **26 CFR Part 1**

[TD 9256]

**RIN 1545–BD97**

#### **Revised Regulations Concerning Disclosure of Relative Values of Optional Forms of Benefit**

**AGENCY:** Internal Revenue Service (IRS), Treasury.

**ACTION:** Final regulations.

**SUMMARY:** This document contains final regulations under section 417(a)(3) of the Internal Revenue Code concerning content requirements applicable to explanations of qualified joint and survivor annuities and qualified preretirement survivor annuities payable under certain retirement plans. These regulations affect sponsors, administrators, participants, and beneficiaries of certain retirement plans. **DATES:** *Effective date:* These regulations are effective March 24, 2006.

*Applicability dates:* The changes to § 1.401(a)–20, A–36, and § 1.417(a)(3)–1 apply as if they had been included in TD 9099 (68 FR 70141). The change to § 1.401(a)–20, Q&A–16, applies as if it had been included in TD 8219 (53 FR 31837).

**FOR FURTHER INFORMATION CONTACT:** Bruce Perlin or Linda Marshall at (202) 622–6090 (not a toll-free number).

#### **SUPPLEMENTARY INFORMATION:**

##### **Paperwork Reduction Act**

The collections of information contained in these final regulations have been previously reviewed and approved